Monoclonal antibodies in cancer therapy

Cancer Immunity

Volumn 12, Issue , 2012, Pages

  Scott, Andrew M ^a,b   Allison, James P ^c,d   Wolchok, Jedd D ^c,e  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antibody identification; Antigenic targets; Tumor surface antigens; Tumor therapy

Indexed keywords

ALEMTUZUMAB; ALPHA FETOPROTEIN; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CATUMAXOMAB; CD20 ANTIGEN; CETUXIMAB; CISPLATIN; GEMTUZUMAB OZOGAMICIN; GLYCOLIPID; GLYCOPROTEIN; IBRITUMOMAB TIUXETAN; IPILIMUMAB; MONOCLONAL ANTIBODY; NIMOTUZUMAB; OFATUMUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; TENASCIN; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUMOR ANTIGEN; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DETECTION; ARTICLE; B CELL LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL ACTIVATION; CELL FUNCTION; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FOLLICULAR LYMPHOMA; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; MALIGNANT ASCITES; MELANOMA METASTASIS; METASTASIS; METASTATIC MELANOMA; NASOPHARYNX CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN TARGETING;

EID: 84862268829     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Rettig WJ, Old LJ. Immunogenetics of human cell surface differen-tiation. Annu Rev Immunol 1989; 7: 481-511. (PMID: 2653374)
2. Van den Eynde BJ, Scott AM. Tumor Antigens. Encyclopedia of Immunology. 1998; 2424-2431.
3. Old LJ, Boyse EA, Stockert E. Typing of mouse leukemias by sero-logical methods. Nature 1964; 22: 777-779. (PMID: 14161198)
4. Boyse EA, Old LJ, Luell S. Genetic determination of the TL (Thy-mus-leukemia) antigen in the mouse. Nature 1964; 22: 779. (PMID: 14161199)
5. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497. (PMID: 1172191)
6. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10: 317-327. (PMID: 20414205)
7. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-316. (PMID: 20414204)
8. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359: 613-626. (PMID: 18687642)
9. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Fol-precht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rou-gier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417. (PMID: 19339720)
10. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51. (PMID: 17611206)
11. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczynicka M, Feldhaus MJ, Kudla AJ, Nielsen UB. Thera-peutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009; 2: ra31. (PMID: 19567914)
12. Canadas I, Rojo F, Arumí-Uría M, Rovira A, Albanell J, Arriola E. C-MET as a new therapeutic target for the development of novel anticancer drugs. Clin Transl Oncol 2010; 12: 253-260. (PMID: 20462834)
13. Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 2010; 12: 361-371. (PMID: 20425077)
14. Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Styli-anou C, Spanevello M, Brechbiel M, Boyd AW, Scott AM, Lack-mann M. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor targeting reagents. Cancer Res 2005; 65: 6745-6754. (PMID: 16061656)
15. Fox NL, Humphreys R, Luster TA, Klein J, Gallant G. Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Recep-tor-1 and Receptor-2 agonists for cancer therapy. Expert Opin Biol Ther 2010; 10: 1-18. (PMID: 19857186)
16. Schliemann C, Neri D. Antibody-based vascular tumor targeting. Recent Results Cancer Res 2010; 180: 201-216. (PMID: 20033385)
17. Deckert PM. Current constructs and targets in clinical develop-ment for antibody-based cancer therapy. Curr Drug Targets 2009; 10: 158-175. (PMID: 19199912)
18. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ. A Phase I dose-escala-tion study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003; 9: 1639-1647. (PMID: 12738716)
19. Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, Carswell EA, Cohen A, Larson SM, Old LJ, Rettig WJ. Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 1994; 12: 1193-1203. (PMID: 8201382)
20. Pillay V, Gan HK, Scott AM. Antibodies in oncology. N Biotechnol 2011; 28: 518-529. (PMID: 21473941)
21. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327. (PMID: 3127726)
22. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nature Rev Drug Discov 2010; 9: 767-774. (PMID: 20811384)
23. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47: 115-123. (PMID: 20350658)
24. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723. (PMID: 20525992)
25. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Rit-ter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ. A Phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth fac-tor receptor. Proc Natl Acad Sci U S A 2007; 104: 4071-4076. (PMID: 17360479)
26. Ravetch J. In vivo veritas: the surprising roles of Fc receptors in immunity. Nat Immunol 2010; 11: 183-185. (PMID: 20157296)
27. Hughes B. Antibody-drug conjugates for cancer: poised to deliver? Nat Rev Drug Discov 2010; 9: 665-667. (PMID: 20811367)
28. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137-1146. (PMID: 16151407)
29. Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, Brechbiel MW, Murone C, Scott AM. Phase I biodistribution and pharmacokinetic study of Lewis Y tar-geting immunoconjugate CMD-193 in patients with advanced epi-thelial cancers. Clin Cancer Res 2009; 15: 6709-6715. (PMID: 19825951)
30. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, Larson SM, Scheinberg DA. A phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immu-nogenicity. Blood 1994; 83: 1760-1768. (PMID: 8142644)
31. Scott AM, Lee FT, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ. Specific targeting, biodistribution and lack of immunoge-nicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma-results of a phase I trial. J Clin Oncol 2001; 19: 3976-3987. (PMID: 11579119)
32. Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, Poon AM, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ. A Phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen. Clin Cancer Res 2007; 13: 3286-3292. (PMID: 17545534)
33. Welt S, Divgi CR, Real FX, Yeh SD, Garin-Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N, Old LJ. Quantita-tive analysis of antibody localization in human metastatic colon cancer: a phase I study of moncolonal antibody A33. J Clin Oncol 1990; 8: 1894-1906. (PMID: 2230877)
34. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Old LJ. Anti-body localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11: 738-750. (PMID: 8478666)
35. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of 89Zr-trastuzumab and PET imag-ing of HER2-positive lesions in patients with metastatic breast can-cer. Clin Pharmacol Ther 2010; 87: 586-592. (PMID: 20357763)
36. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010; 467: 543-549. (PMID: 20882008)
37. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, Mendelsohn J. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991; 83: 97-104. (PMID: 1988695)
38. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer 2008; 8: 579-591. (PMID: 18596824)
39. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740. (PMID: 19720927)
40. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634. (PMID: 18316791)
41. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal can-cer. N Engl J Med 2008; 359: 1757-1765. (PMID: 18946061)
42. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Lau-rent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379. (PMID: 18202412)
43. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812-1821. (PMID: 21047225)
44. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacob-son FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280-9290. (PMID: 1901901)
45. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Par-sons SL. The trifunctional antibody catumaxomab for the treatmentof malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127: 2209-2221. (PMID: 20473913)
46. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclo-nal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009; 9: 1199-1206. (PMID: 19624281)
47. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW. Piv-otal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 2005; 23: 1538-1547. (PMID: 15735129)
48. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4. Science 1996; 271: 1734-1736. (PMID: 8596936)
49. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL. Phase I study of single-agent anti-pro-grammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175. (PMID: 20516446)
50. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331: 1612-1616. (PMID: 21436454)
51. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2 specific immunity during treatment with Trastuzumab and chemotherapy. Clin Cancer Res 2007; 15: 5133-5143. (PMID: 17785568)
52. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclo-nal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28: 4390-4399. (PMID: 20697078)
53. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345-352. (PMID: 20414207)
54. Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Oncogene 2009; 11: 448-458. (PMID: 19412429)
55. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL. Ipilimumab and a poxviral vaccine target-ing prostate-specific antigen in metastatic castration-resistant pros-tate cancer: a phase I dose-escalation trial. Lancet Oncol 2012; epub ahead of print. (PMID: 22326924)